The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAccsys Tech Regulatory News (AXS)

Share Price Information for Accsys Tech (AXS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 55.00
Bid: 55.00
Ask: 58.00
Change: -0.50 (-0.88%)
Spread: 3.00 (5.455%)
Open: 55.00
High: 55.00
Low: 55.00
Prev. Close: 57.00
AXS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

24 Nov 2014 07:00

RNS Number : 7703X
Accsys Technologies PLC
24 November 2014
 



 

AIM: AXS

NYSE Euronext Amsterdam: AXS

24 November 2014

 

ACCSYS TECHNOLOGIES PLC ("Accsys" or "the Company")

 

INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2014

 

Accsys, the chemical technology group, focused on the acetylation of wood, today announces interim results for the six months ended 30 September 2014.

 

Unaudited six months to 30 Sept 2014

Unaudited six months to 30 Sept 2013

Change

Total Group Revenue

€21.8m

€15.8m

+38%

Gross profit

€5.0m

€3.5m

+46%

Underlying EBITDA*

Underlying loss before tax*

(€1.9m)

(€3.1m)

(€2.5m)

(€3.7m)

Improved 24%

Improved 16%

Loss before tax

(€6.2m)

(€3.8m)

63% decrease

Period end cash balance

€13.5m

€15.2m

-11%

 

*Underlying EBITDA and loss before tax are stated before exceptional items of €3.1m recorded in respect of arbitration relating to the Diamond Wood licence agreement.

 

Highlights

· Continued trend of strong revenue growth, with revenue from the sale of Accoya® increased by 43% to €19.8m in the first half of the year compared to the corresponding period last year;

· Total revenue increased 38% compared to the corresponding period last year, and by 23% compared to the preceding six month period;

· Manufacturing segment profitability continues to improve, recording EBITDA of €3.1m (2013: €0.9m) as a result of record production levels; gross manufacturing profit margin increased from 19% to 23%;

· Total Accoya® volume sold increased by 39% to 16,840 cubic metres in the period (2013: 12,102 cubic meters);

· Strong balance sheet maintained with cash balance of €13.5m at 30 September 2014;

· 60% reduction in cash out-flow from operating activities (before changes in working capital and exceptional items) to €0.7m (2013: €1.6m) as a result in improvement in profitability;

· Significant progress made with Solvay, our Accoya® licensee;

· Accoya® distributor and agency agreements now in place covering most of Europe, Australia, Canada, Chile, China, India, Japan, Mexico, Morocco, New Zealand, South Africa, parts of South-East Asia and the USA; and

· Patrick Shanley appointed as full time Chairman.

Paul Clegg, Chief Executive commented: "This latest set of results, in particular those achieved by the Manufacturing segment, provides further evidence that the extensive sales and marketing efforts we have carried out in recent years are delivering real benefit, resulting in continued, impressive growth in Accoya® sales and significant improvement of profitability. Our balance sheet remains strong and we are confident of achieving a cash-flow positive position in the foreseeable future.

 

"Our immediate challenge is for additional capacity through the construction of additional Accoya plants in order to meet the growing global demand for our products. We are confident of achieving this through our relationship with Solvay, and we continue to explore additional opportunities in order to achieve the goal of adding Accoya capacity to enable Accsys to maximise the value generated from our products and technologies."

There will be a presentation relating to these results at 10:00 GMT on Monday 24 November 2014. The presentation will take the form of a web based conference call, details of which are below:

 

Webcast link:

 

Click here or copy and paste ALL of the following text into your browser: 

 

http://www.media-server.com/m/p/kkwcss2y

 

Conference call details for participants:

 

Participant Telephone Number: +44(0)20 3427 1915 UK Toll

Confirmation Code: 9263307

 

Participants will have to quote the above code when dialling into the conference.

 

 

 

For further information, please contact:

 

Accsys Technologies PLC

Paul Clegg, CEO

Hans Pauli, COO

Will Rudge, FD

 

 via Blythe Weigh Communications

Numis Securities

Nominated Adviser: Oliver Cardigan

Corporate Broking: Christopher Wilkinson

Ben Stoop

+44 (0) 20 7260 1000

 

Blytheweigh

 

Paul Weigh

Alex Shilov

 

+44 (0) 20 7138 3204

+44 (0) 7989 129658

+44 (0) 7989 394027

 

Off the Grid (The Netherlands)

 

Frank Neervoort

Giedo Van Der Zwan

 

+31 681 734 236

+31 624 212 238

Accsys Technologies PLC

 

Chairman's statement

 

Overview

I am pleased by the progress Accsys has made over the last period. Demand for Accoya® continues to increase, we are manufacturing at record levels and we have made significant progress in developing the long term potential for Accoya® with Solvay. Following our review of the composition of the Board, I am honoured to have been appointed as your Chairman on a continuing basis. I am also excited about the prospect of being able to strengthen and add to our Board, and look forward to being able to make a further announcement in that regard shortly.

 

Accoya® revenue increased by 43% to €19.8m in the period, reflecting the continuing increase in demand for our products, while total revenue increased by 38% to €21.8m. Manufacturing profitability also continues to improve, with gross manufacturing profit margin improving from 19% to 23% and the manufacturing segment recording EBITDA of €3.1m compared to €0.9m in the previous year. 

 

The Manufacturing segment continues to benefit from the economies of scale achieved from record Accoya®production which enabled sales volumes to increase by 39% to 16,840 cubic metres. Together with a price increase implemented in the second half of the previous financial year, improved profitability helped the Group to reduce its underlying EBITDA loss from €2.5m to €1.9m. Group loss before tax, before exceptional items of €3.1m, decreased by 16% to €3.1m.

 

Our balance sheet remains strong, with a cash balance of €13.5m as at 30 September 2014 (€15.2m as at 31 March 2014). Part of this reduction was due to cash outflows from operating activities before changes in working capital, however this outflow reduced by 60% to €0.7m when excluding exceptional items.

 

Solvay Acetow has announced that it is progressing to the next stage of the preparation of the Accoya plant in Freiburg, which includes amongst other works the completion of the Detailed Engineering and the physical clearing and preparation of the site. The next construction milestone is mid-2015, in line with the expected schedule of completion by 2016. This follows on from the binding term sheet agreed with Solvay in August 2014 in respect of a three year global co-operation agreement to develop Accoya® under which Solvay is expected to engage Accsys to carry out targeted marketing activities outside of Europe. In addition the term sheet allows for Accsys to grant Solvay a non-exclusive global Accoya® licence option for available regions and for Solvay to grant Accsys the option to invest in a substantial minority share in the European project and future Accoya® production projects. The full marketing agreement is expected to be finalised in December 2014.

 

Our joint venture with Ineos, Tricoya Technologies Limited ('TTL') also continues to progress the development of Tricoya. Market development activities continue with Medite and Masisa, with Masisa extending the duration of its licence option for Latin America. The progress is demonstrated by sales of Accoya to Medite for the manufacture of Medite Tricoya, prior to dedicated facilities being built, with revenue having increased by 68% to €2.4m compared to the same period last year. The licence with Medite remains conditional upon the approval from its Board of Directors.

 

We have recorded an exceptional cost of €3.1m relating to the arbitration ruling received in the period in respect of the dispute with Diamond Wood, following our decision to terminate the licence agreement in August 2013. The charge reflects an award of damages of €250,000, payment of Diamond Wood's costs of €2.1m and our own costs of €0.7m.

 

 

Outlook 

 

The Accoya® sales outlook remains strong and we expect revenue to continue to grow in the second half of the year. Accoya orders are now in place for approximately the next five months of production with further orders having been received for the remainder of the year, reflecting a significantly longer outlook than this time last year.

Further sales growth is also possible as we continue to increase the efficiency of our processes and operating procedures which enable us to continue to exploit the Arnhem plant and increase its capacity. As a result we expect our profitability to continue to improve and to achieve a cash-flow positive position in the foreseeable future.

The relationship with our licensed partners, Solvay and Medite, will continue to progress as we continue to develop how to best exploit the significant value which has been created in our intellectual property and I look forward to reporting further developments in due course.

 

I am confident that we remain in a strong position to continue the transition from a R&D company into one focused on fully commercialising our technologies and the experience we have developed.

 

Patrick Shanley

Chairman

21 November 2014

Accsys Technologies PLC

 

Chief Executive's statement

 

Introduction

 

Accsys has made further significant progress in its three main business areas. We have achieved record sales and production volumes from our Arnhem plant, further developed the relationship with our existing partners and continued our research and development programs which have involved improving a number of our manufacturing processes.

 

This progress was evident at our fourth Worldwide Accoya® wood sales conference held in September in Ireland. The three day conference involved around 130 participants, an increase from 90 last year, and included 46 existing or potential customers from 29 countries. Representatives from Solvay, Medite and Masisa also attended and the conference provided an opportunity for all participants to further understand the benefits of Tricoya and included a visit to Medite's facility in Clonmel.

 

Progress with Accoya® manufacturing and sales

 

Revenue from the sale of Accoya® increased by 43% to €19.8m in the first half of the year compared to the same period in the previous year. Revenue from the sale of Accoya also increased by 28% in the first half of the year compared to the second half of the previous financial year.

 

Growth in the period has primarily been attributable to existing distributors and has been experienced in most regions with the exception of the Benelux which has been impacted particularly by the difficult economic conditions affecting the construction industry. In contrast, the United Kingdom, one of our most established regions, which has also benefited from an improving economy, grew by 109%, all derived from existing distributors. We have added new distributors in the USA, Australia and Europe amongst other countries and we now have a total of 55 distribution or agency agreements covering most of Europe, Australia, Chile, China, India, Israel, Japan, Morocco, New Zealand, North America, South Africa and parts of South-East Asia, excluding those in Diamond Wood's territory.

 

The growth in Accoya® sales continues to result in improved profitability from our manufacturing operations, with our manufacturing gross margin increasing to 23% (2013: 19%) and the manufacturing EBITDA to €3.1m (2013: €0.9m). This has resulted from higher volumes, a price increase implemented in the later part of the previous financial year, economies of scale associated with operating a chemical plant together with operational and process improvements.

 

During the period, we sold 16,840 cubic meters of Accoya®, a 39% increase compared to the same period in the previous year. We successfully optimised short term production constraints and recently completed our annual maintenance stop during which we implemented changes which will help enable us to increase manufacturing capacity. A further price increase is being implemented in the second half of the financial year for all of our customers which we expect to further improve profitability.

 

The Manufacturing segment's profitability helps demonstrate the potential returns achievable from manufacturing Accoya® on a larger scale. This is particularly the case when taking account of the economies of scale expected from operating a larger plant and when considering that our profitability has been impacted by significant volumes (approximately 18% of total Accoya® volume in the period) sold to Medite at lower prices, reflecting the on-going Tricoya market development activities.

 

We continue to build upon Accoya's® reputation in the market place. For example, recent joint research from Imperial College London and Heriot Watt University confirmed an estimated service life of Accoya windows of a minimum of 90 years. In addition, Accoya has increased the eligible credits with its use within the US Green Building Council's LEED program, a leading sustainable building program.

 

 

Licensing

 

In August 2014 our licenced partner Solvay, the Belgian chemical group, confirmed its intention to build a 63,000 cubic meter Accoya® wood production plant. Solvay Acetow has announced that it is progressing to the next stage of the preparation of the Accoya plant in Freiburg, which includes amongst other works the completion of the Detailed Engineering and the physical clearing and preparation of the site. The next construction milestone is mid-2015, in line with the expected schedule of completion by 2016.

 

In addition, we entered into a binding term sheet with Solvay, in respect of a three year non-exclusive global co-operation agreement to develop Accoya® under which Solvay will engage Accsys to carry out targeted marketing activities to develop the Accoya® market outside of Europe.

 

Under the term sheet Accsys is also to grant Solvay a non-exclusive global Accoya® licence option for defined available regions under conditions that reflect the improved acceptance of Accoya® in the market. In addition, Solvay is to grant Accsys the option to invest up to a substantial minority share in both the European project and in any future Accoya® production projects. Such a partnership would allow Accsys to benefit from future manufacturing profits of any Accoya® manufacturing plants that Solvay may construct under licence.

 

Accsys and Solvay are working together to complete the various full agreements to implement the binding term sheet. The first of these agreements, in respect of marketing, is expected to be entered into by the end of December 2014 with the remaining agreements following in 2015.

 

Following the arbitration ruling received in July 2014 in respect of the Diamond Wood licence agreement, Diamond Wood are obliged to resume endeavours towards the construction of an Accoya® plant in the Far East, together with the promotion, marketing and selling of Accoya to customers in China and the Far East.

 

Tricoya® Technologies Limited ('TTL')

 

TTL, our joint venture with Ineos formed to exploit Accsys' intellectual property associated with Tricoya® and to accelerate its global deployment, has continued to make solid progress.

 

The market evaluation of Medite Tricoya® continues to be positive with increasing acceptance of the product leading to a significant increase in sales to customers. This is partly reflected by the sales of Accoya® to Medite for the manufacture of Medite Tricoya®, prior to dedicated facilities for wood acetylation being built. These sales increased by 68% to €2.4m in the period compared to €1.4m in the corresponding period in the previous year.

 

Medite has a joint development, production and distribution licence with TTL. This allows them to build and operate a plant to manufacture, market and sell Tricoya, with an initial plant capacity of 30,000 metric tonnes per annum; however it remains conditional upon the approval of Medite's board of directors.

 

In May 2014 TTL's partner in Latin America, Masisa, took a step forward with the extension of its licence option and agreement to carry out an evaluation of Tricoya® including market testing, product testing and development of finished end-products with the launch of Masisa Tricoya® Super MDF.

 

Masisa has industrial facilities in Chile, Argentina, Brazil, Venezuela and Mexico as well as commercial operations in over 40 countries. Its main panel products are MDP (medium density particleboard), MDF (medium density fibreboard) and Melamine boards. The option agreement, originally signed in April 2012, if exercised, grants Masisa exclusive production and distribution rights for Tricoya® for the Latin American market (excluding Brazil, for which the sales and marketing rights are non-exclusive) in consideration for the payment of technology and royalty fees by Masisa to TTL.

 

TTL continues to progress a number of other opportunities to ensure that the Tricoya® intellectual property is fully exploited.

 

 

Intellectual property

 

Accsys has continued to file new patent applications in the recent period and now owns eight different Accoya® patent families, with 26 patents granted and 45 further applications, filed in a total of 36 countries world-wide.

 

In respect of Tricoya®, TTL benefits from five published patent families with a total of 73 published product and process patent applications filed in key territories across the world.

 

Our principal brands, Accoya®, Accsys, Tricoya® and the Trimarque Device, including Arabic, Chinese and Japanese transliterations, are protected by trademark registration in 56 countries throughout the world with pending applications in a further single country. These registrations and applications cover our corporate identity and the products we sell as well as those to be sold by our licensees and distributors.

 

Outlook

 

Accsys continues to make significant progress in the manufacture and sales of Accoya and the resulting improvement in profitability means that I am increasingly confident the group will move into a cash-flow break even position in the foreseeable future.

 

We continue to transition into a new phase of development of the Company which is focussed on meeting the ever increasing global demand for our products. I believe the improvements we have made with our sales, marketing, process, manufacturing, research and development means we are very well positioned to take advantage of the significant value represented by our intellectual property.

 

 

Paul Clegg

Chief Executive

21 November 2014

Accsys Technologies PLC

 

Financial Review

 

Statement of comprehensive income

 

Group revenue increased by 38% to €21.8m for the six months ended 30 September 2013 (2013: €15.8m). Revenue from Accoya® (included within manufacturing revenue) increased by 43% to €19.8m, reflecting growth driven by demand for Accoya. No licence income was recorded in the period (2013: €525,000), reflecting the progress with construction of Solvay's plant in the period which was pending approval by Solvay to progress to the next stage of construction. Further licence income is expected to be recognised in the next period following Solvay's confirmation they are to progress to next stage of the preparation of the Accoya plant in Freiburg. Other revenue, which mainly includes the sale of acetic acid as a by-product from our production process, increased by 43% to €2.0m (2013: €1.4m) as a result of higher production levels.

 

Gross margin increased from 22% to 23% compared to the same period in the previous year. This was driven by a significant improvement in the gross manufacturing margin which increased from 19% to 23%, but which was offset by the absence of licence income as noted above. This margin is expected to improve further as our production volumes increase and we benefit further from economies of scale and a price increase being implemented in the second half of the financial year.

 

Other operating costs, before exceptional items, increased from €6.8m to €7.6m. The increase is partly attributable to an increase in sales and marketing costs, which increased by €0.2m, noting that the costs in the previous year were lower due to the timing of certain exhibitions. In addition there was an increase in Administration costs of €0.5m, which included higher professional costs associated with business development activities. Total staff costs included in other operating costs increased by €0.4m predominantly due to inflationary wage increases, the weakening of the Euro and a higher share based payment charge.

 

Research and development costs reduced marginally from €553,000 to €461,000, as a result of a larger proportion of research and development activities been carried out on behalf of TTL in the period.

 

Exceptional costs of €3.1m relate to the Diamond Wood arbitration process. The balance includes a provision for €2.4m in respect of Diamond Wood's costs of €2.1m and the awards for damages of €250,000, both of which are payable to Diamond Wood in the period after 30 September 2014. In addition, Accsys incurred a further €0.7m in respect of its own legal costs in the period.

 

The share of joint venture loss of €0.5m compares to €0.4m loss recorded in the previous financial year. Within this, TTL recorded revenue of €0.2m attributable to the licence agreement with Medite (2013: €0.1m) and €0.2m of income associated with the European Community's Life+ subsidy that the Medite Tricoya project was awarded last year.

 

Group headcount increased from 102 as at 30 September 2013, to 106 as at 31 March 2014 and 113 as at 30 September 2014, with the increase predominantly due to direct production staff with costs included in cost of sales.

 

The decrease in the loss before tax before exceptional items by 16% to €3.1m (2013: €3.7m) can largely be attributed to the improvement in revenue and gross margin. After exceptional items, loss before tax increased by 63% to €6.2m.

 

The tax charge of €0.5m (2013: €0.3m) is based on our expected tax rate for the year in accordance with IAS 34 and is attributable to the profits arising from manufacturing operations, offset by expected research and development tax credits.

 

 

Cash flow and financial position

 

At 30 September 2014, the Group held cash balances of €13.5m, representing a €1.7m reduction compared to 31 March 2014. This reduction is after taking account of short term borrowings of €1.5m, such that the reduction in net cash in the period was €3.2m (2013: €3.5m).

 

Cash out-flow from operating activities before changes in working capital and excluding exceptional items of €0.8m, was €0.7m, a 60% reduction compared to the same period in the prior year (2013: €1.6m).

 

In addition, cash out-flows were also attributable to an increase in working capital of €0.5m (2013: cash out-flow due to increase in working capital of €1.0m), investment in our joint venture TTL of €0.9m (2013: €0.4m), purchases of property plant and equipment of €0.5m (2013: €0.4m) and capitalised development costs of €0.1m (2013: €0.3m). These have been offset by a €0.2m receipt of research and development tax credits (2013: €0.3m).

 

The net cash balance is expected to decrease further in the second half of the year as a result of the payment of awards in respect of the Diamond Wood arbitration and the transfer of €0.9m to TTL relating to the Life+ subsidy following the formal assignment from Accsys to TTL. However the reduction in underlying cash out-flows referred to above reflects the overall improvement in profitability and helps confirm that the Group is expected to become cash-flow break even in the foreseeable future as sales volumes and gross margin continues to improve.

 

Trade and other receivables increased to €6.4m (2013: €4.3m) as a result of the increased revenue. Inventory increased to €6.5m (2013: €5.4m), with the lower relative increase reflecting a continued focus on managing our inventory levels.

 

Trade and other payables, which increased to €9.8m (2013: 4.4m) included €1.5m of deferred income in respect of payments received from Solvay, together with €0.9m held in respect of the Life+ subsidy as mentioned above.

 

Risks and uncertainties

 

The Group's principal risks and uncertainties are unchanged from those set out in its 2014 Annual Report.

 

Going concern

 

These condensed financial statements are prepared on a going concern basis, which assumes that the Group will continue in operational existence for the foreseeable future, which is deemed to be at least 12 months from the date these interim results were approved.

 

As part of the Group's going concern review, the Directors have reviewed the Group's trading forecasts and working capital requirements for the foreseeable future. These forecasts indicate that, in order to continue as a going concern, the Group is dependent on achieving certain operating performance measures relating to the production and sales of Accoya® wood from the plant in Arnhem and the collection of on-going working capital items in line with internally agreed budgets.

 

The Directors have considered the internally agreed budgets and performance measures and believe that appropriate controls and procedures are in place or will be in place to make sure that these are met. The Directors believe, while some uncertainty inherently remains in achieving the budget, in particular in relation to market conditions outside of the Group's control, that there are a sufficient number of alternative actions and measures that can be taken in order to achieve the Group's medium and long term objectives. Therefore, the Directors believe that the going concern basis is the most appropriate on which to prepare the financial statements.

 

William Rudge

Finance Director

21 November 2014

Accsys Technologies PLC

 

Directors responsibility statement

 

The Directors confirm to the best of their knowledge:

 

· The condensed financial statements contained in the half year report have been prepared in accordance with IAS 34 "Interim Financial Reporting" as adopted by the EU;

 

· The interim results include a fair review of the information required by DTR 4.2.7R being an indication of important events that have occurred during the first six months of the financial year and a description of the principal risks and uncertainties for the remaining six months of the financial year; and

 

· The interim Management Report (Narrative) include a fair review of the information required by DTR 4.28R being disclosure of related party transactions and changes therein since the last annual report.

 

 

By order of the Board

 

 

 

Angus Dodwell

Company Secretary

21 November 2014

 

Accsys Technologies PLC

 

Consolidated statement of comprehensive income for the six months ended 30 September 2014

 

Note

Unaudited

Unaudited

Unaudited

Unaudited

Unaudited

Unaudited

Audited

Audited

Audited

6 months

6 months

6 months

6 months

6 months

6 months

Year

Year

Year

ended

ended

Ended

ended

ended

ended

ended

ended

ended

30 Sept

30 Sept

30 Sept

30 Sept

30 Sept

30 Sept

31 March

31 March

31 March

2014

2014

2014

2013

2013

2013

2014

2014

2014

€'000

€'000

€'000

€'000

€'000

€'000

€'000

€'000

€'000

Before exceptional items

Exceptional items(note 4)

Total

Before exceptional items

Exceptional items(note 4)

Total

Before exceptional items

Exceptional items(note 4)

Total

Accoya® wood revenue

19,777

-

19,777

13,869

-

13,869

29,293

-

29,293

Licence revenue

-

-

-

525

-

525

1,134

-

1,134

Other revenue

2,009

-

2,009

1,375

-

1,375

3,085

-

3,085

Total revenue

2

21,786

-

21,786

15,769

-

15,769

33,512

-

33,512

Total cost of sales

(16,768)

-

(16,768)

(12,300)

-

(12,300)

(25,753)

-

(25,753)

Gross profit

5,018

-

5,018

3,469

-

3,469

7,759

-

7,759

Other operating costs

3

(7,645)

(3,080)

(10,725)

(6,757)

(71)

(6,828)

(14,247)

(726)

(14,973)

Loss from operations

(2,627)

(3,080)

(5,707)

(3,288)

(71)

(3,359)

(6,488)

(726)

(7,214)

Share of joint venture loss

6

(465)

-

(465)

(390)

-

(390)

(905)

-

(905)

Finance income

57

-

57

79

-

79

155

-

155

Finance expense

(112)

-

(112)

(122)

-

(122)

(226)

-

(226)

Loss before taxation

(3,147)

(3,080)

(6,227)

(3,721)

(71)

(3,792)

(7,464)

(726)

(8,190)

Tax charge

(475)

-

(475)

(340)

-

(340)

(699)

-

(699)

Loss for the period

(3,622)

(3,080)

(6,702)

(4,061)

(71)

(4,132)

(8,163)

(726)

(8,889)

Gain/loss arising on translation of foreign operations

21

-

21

(32)

-

(32)

(36)

-

(36)

Total comprehensive loss for the period

(3,601)

(3,080)

(6,681)

(4,093)

(71)

(4,164)

(8,199)

(726)

(8,925)

Basic and diluted loss per ordinary share

5

€(0.04)

€(0.08)

€(0.05)

€(0.05)

€(0.09)

€(0.10)

 

 

 

The notes set out on pages 15 to 21 form part of these condensed financial statements.

 

Accsys Technologies PLC

 

Consolidated statement of financial position at30 September 2014

 

Unaudited

Unaudited

Audited

6 months

6 months

Year

ended

ended

ended

30 Sept

30 Sept

31 March

Note

2014

2013

2014

€'000

€'000

€'000

Non-current assets

Intangible assets

8,284

8,398

8,333

Investment in joint venture

6

710

64

340

Property, plant and equipment

7

20,151

21,696

20,740

Deferred tax

-

422

-

29,145

30,580

29,413

Current assets

Inventories

6,545

5,433

6,053

Trade and other receivables

6,370

4,251

4,477

Cash and cash equivalents

13,516

16,937

15,185

Corporation tax

284

384

446

26,715

27,005

26,161

Current liabilities

Trade and other payables

(9,822)

(3,444)

(5,557)

Short term borrowings

(1,484)

-

-

Obligation under finance lease

(264)

(264)

(264)

Corporation tax

(548)

-

(12,118)

(3,708)

(5,821)

Non-current liabilities

Obligation under finance lease

(1,843)

(1,905)

(1,871)

(1,843)

(1,905)

(1,871)

Net current assets

14,597

23,297

20,340

Total net assets

41,899

51,972

47,882

Equity and reserves

Share capital - Ordinary shares

8

4,436

4,389

4,392

Share premium account

128,677

128,648

128,648

Capital redemption reserve

148

148

148

Warrants reserve

235

235

235

Merger reserve

106,707

106,707

106,707

Retained deficit

(198,309)

(188,133)

(192,223)

Own shares

(38)

(48)

(47)

Foreign currency translation reserve

43

26

22

Total equity

41,899

51,972

47,882

 

The notes set out on pages 15 to 21 form part of these condensed financial statements.

 

Accsys Technologies PLC

 

Consolidated statement of changes in equity for the six months ended 30 September 2014

Share capital Ordinary

Share premium

Capital redemption reserve

Warrant reserve

Merger reserve

Own Shares

Foreign currency translation reserve

Retained earnings

 Total

€'000

€'000

€'000

€'000

€'000

€'000

€'000

€'000

€'000

Balance at30 Sept 2013(unaudited)

4,389

128,648

148

235

106,707

(48)

26

(188,133)

51,972

Total comprehensive income/(expense) for the period

-

-

-

-

-

-

(4)

(4,757)

(4,761)

Expiry of warrants

-

-

-

-

-

-

-

-

-

Share based payments

-

-

-

-

-

-

-

667

667

Shares issued

3

-

-

-

-

1

-

-

4

Premium on shares issued

-

-

-

-

-

-

-

-

-

Share Warrants issued

-

-

-

-

-

-

-

-

-

Balance at31 March 2014

4,392

128,648

148

235

106,707

(47)

22

(192,223)

47,882

Total comprehensive income/(expense) for the period

-

-

-

-

-

-

21

(6,702)

(6,681)

Expiry of warrants

-

-

-

-

-

-

-

-

-

Share based payments

-

-

-

-

-

-

-

616

616

Shares issued

44

29

-

-

-

9

-

-

82

Premium on shares issued

-

-

-

-

-

-

-

-

-

Share Warrants issued

-

-

-

-

-

-

-

-

-

Balance at30 Sept 2014(unaudited)

4,436

128,677

148

235

106,707

(38)

43

(198,309)

41,899

 

 

The notes set out on pages 15 to 21 form part of these condensed financial statements.

 

Further to the passing of all resolutions at the Company's AGM held on 11 September 2014, the entire issued share capital of the Company was consolidated on a 5:1 basis with effect from 12 September 2014. Accordingly, all figures concerning the number of shares stated below represent the new €0.05 Ordinary Shares.

 

Own shares represents 783,597 €0.05 Ordinary Shares issued to an Employee Benefit Trust ('EBT') at nominal value on 18 August 2014.

 

In addition, of the 953,133 €0.05 Ordinary Shares which had been issued to the EBT at nominal value on 9 July 2013, 945,133 Ordinary Shares vested on 8 August 2014. Of these beneficiaries elected to sell 361,033 Ordinary shares in the market. As at 30 September 2014, 223,425 Ordinary Shares remained pending sale by the EBT in the market.

 

On 18 August 2014, a total of 27,819 of €0.05 Ordinary shares were issued to a trust under the terms of the Employee Share Participation Plan.

 

On 12 August 2014, a total of 99,570 of €0.05 Ordinary shares were issued and released to employees together with the 99,570 of €0.05 Ordinary shares issued to trust on 12 August 2013.

 

Accsys Technologies PLC

 

Consolidated statement of cash flow for the six months ended 30 September 2014

 

Unaudited

Unaudited

Audited

6 months

6 months

Year End

30 Sept

30 Sept

31 March

2014

2013

2014

€'000

€'000

€'000

Profit before taxation

(6,227)

(3,792)

(8,190)

Adjustments for:

Amortisation of intangible assets

177

175

352

Depreciation of property, plant and equipment

1,042

996

2,024

Net gain on disposal of property, plant and equipment

-

-

77

Recognition of reduction of investment in joint venture

530

398

922

Finance expense

55

43

71

Provisions not yet settled

2,360

-

-

Equity-settled share-based payment expenses

616

509

1,177

Cash outflows from operating activities before changes in working capital (See note*)

 (1,447)

(1,671)

(3,567)

(Increase)/decrease in trade and other receivables

(2,374)

(567)

(253)

Increase in deferred income

1,508

-

Increase in inventories

(433)

(572)

(1,194)

Decrease/(increase) in trade and other payables

832

144

1,757

Net cash absorbed by operating activities before tax

(1,914)

(2,666)

(3,257)

Tax received

235

344

344

Net cash absorbed by operating activities

(1,679)

(2,322)

(2,913)

Cash flows from investing activities

Interest received

57

79

124

Expenditure on capitalised internal development

(128)

(348)

(459)

Purchase of property, plant and equipment

(452)

(420)

(572)

Purchase of intangible assets

-

(23)

(23)

Investments in joint ventures

(900)

(400)

(1,200)

Net cash absorbed by investing activities

(1,423)

(1,112)

(2,130)

Cashflows from financing activities

Finance expenses

(28)

(19)

(54)

Interest Paid

(123)

(122)

(226)

Proceeds from issue of share capital

83

69

70

Short term borrowings

1,484

-

-

Net cash from financing activities

1,416

(72)

(210)

Net decrease in cash and cash equivalents

(1,686)

(3,506)

(5,253)

Effect of exchange differences on restatement of non Euro functional currency

17

(23)

(29)

Opening cash and cash equivalents

15,185

20,466

20,467

Closing cash and cash equivalents

13,516

16,937

15,185

* Note: Included within cash outflows from operating activities before changes in working capital is €796,000 in respect of Exceptional costs (Six months ended September 2013: €31,000; Year ended 31 March 2014 €498,000.)

 

The notes set out on pages 15 to 21 form part of these interim financial statements.

Accsys Technologies PLC

 

Notes to the financial statements for the six months ended 30 September 2014

 

 

1. Accounting policies

 

Principal activities of the business

 

The principal activity of the Group is the production and sale of Accoya® solid wood and licensing of technology for the production and sale of Accoya® wood and Tricoya® wood elements via the Company's 100% owned subsidiaries, Titan Wood Limited, Titan Wood B.V., Titan Wood Technology B.V. and Titan Wood Inc (collectively the 'Group') and its joint-venture with INEOS, Tricoya Technologies Limited. Manufactured through the Group's proprietary acetylation processes, these products exhibit superior dimensional stability and durability compared with alternative natural, treated and modified woods as well as more resource intensive man-made materials.

 

Basis of accounting

 

The Group's condensed financial statements in these interim results have been prepared in accordance with International Accounting Standard (IAS) 34 "interim financial reporting" as adopted for use in the European Union. The financial information for the six months ended 30 September 2014 and the six months ended 30 September 2013 is unaudited. The comparative financial information for the full year ended 31 March 2014 does not constitute the group's statutory financial statements for that period although it has been derived from the statutory financial statements for the year then ended. A copy of those statutory financial statements has been delivered to the Registrar of Companies and which were approved by the Board of Directors on the 2 July 2014. The auditors' report on those accounts was unqualified and did not contain a statement under 498(2) or 498(3) of the Companies Act 2006.

 

The preparation of interim financial statements requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

 

In preparing these interim financial statements, the significant judgements made by management in applying the group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements for the year ended 31 March 2014.

 

Changes in accounting policies

 

No new accounting standards, amendments or interpretations have been adopted in the period which have any impact on these condensed financial statements, or are expected to affect the Group's 2015 Annual Report other than as noted below. The accounting policies and methods of computation are consistent with those applied in the 31 March 2014 annual financial statements other than as noted below for exceptional items.

 

Exceptional items

 

Exceptional items are events or transactions that fall outside the ordinary activities of the Group and which by virtue of their size or incidence, have been separately disclosed in order to improve a reader's understanding of the financial statements. These include items relating to the restructuring of a significant part of the Group, impairment losses (or the reversal of previously recorded exceptional impairments), expenditure relating to the integration and implementation of significant acquisitions and other one-off events or transactions. See note 4 for details of exceptional items.

 

Going concern

 

These condensed financial statements are prepared on a going concern basis, which assumes that the Group will continue in operational existence for the foreseeable future, which is deemed to be at least 12 months from the date these interim results were approved. As part of the Group's going concern review, the Directors have reviewed the Group's trading forecasts and working capital requirements for the foreseeable future. These forecasts indicate that, in order to continue as a going concern, the Group is dependent on achieving certain operating performance measures relating to the production and sales of Accoya® wood from the plant in Arnhem and the collection of on-going working capital items in line with internally agreed budgets.

 

The Directors have considered the internally agreed budgets and performance measures and believe that appropriate controls and procedures are in place or will be in place to make sure that these are met. The Directors believe, while some uncertainty inherently remains in achieving the budget, in particular in relation to market conditions outside of the Group's control, that there are a sufficient number of alternative actions and measures that can be taken in order to achieve the Group's medium and long term objectives. Therefore, the Directors believe that the going concern basis is the most appropriate on which to prepare the financial statements.

 

2. Segmental reporting

 

The Group's business is the development, commercialisation and licensing of proprietary technology for the manufacture of Accoya® wood, Tricoya® wood elements and related acetylation technologies. Segmental reporting is divided between licensing activities, the manufacturing and sale of Accoya® and research and development activities.

 

Result by Segment:

Licensing

Unaudited

Unaudited

Audited

6 months

6 months

Year

ended

ended

ended

30 Sept

30 Sept

31 March

2014

2013

2014

€'000

€'000

€'000

Revenue

-

525

1,134

Cost of sales

-

-

-

Gross profit/(loss)

-

525

1,134

Other operating costs

(4,248)

(3,270)

(6,954)

Exceptional Items

(3,080)

(71)

(726)

Other operating costs

(7,328)

(3,341)

(7,680)

Loss from operations

(7,328)

(2,816)

(6,546)

Loss from Operations

(7,328)

(2,816)

(6,546)

Depreciation and amortisation

204

207

412

EBITDA

(7,124)

(2,609)

(6,134)

 

 

 

Manufacturing

Revenue

21,786

15,244

32,378

Cost of sales

(16,768)

(12,300)

(25,753)

Gross profit/(loss)

5,018

2,944

6,625

Other operating costs

(2,936)

(2,934)

(6,142)

Profit/(loss) from operations

2,082

10

483

Profit/(loss) from operations

2,082

10

483

Depreciation and amortisation

994

931

1,910

EBITDA

3,076

941

2,393

 

 

 

Research and Development

Revenue

-

-

-

Cost of sales

-

-

-

Gross profit/(loss)

-

-

-

Other operating costs

(461)

(553)

(1,151)

Loss from operations

(461)

(553)

(1,151)

Loss from Operations

(461)

(553)

(1,151)

Depreciation and amortisation

20

33

54

EBITDA

(441)

(520)

(1,097)

 

 

Total

Revenue

21,786

15,769

33,512

Cost of sales

(16,768)

(12,300)

(25,753)

Gross profit/(loss)

5,018

3,469

7,759

Other operating costs

(7,645)

(6,757)

(14,247)

Exceptional Items

(3,080)

(71)

(726)

Other operating costs

(10,725)

(6,828)

(14,973)

Loss from operations

(5,707)

(3,359)

(7,214)

Share of joint venture loss

(465)

(390)

(905)

Finance income

57

79

155

Finance expense

(112)

(122)

(226)

Loss before taxation

(6,227)

(3,792)

(8,190)

Loss from Operations

(5,707)

(3,359)

(7,214)

Share of joint venture loss

(465)

(390)

(905)

Depreciation and amortisation

1,218

1,171

2,376

EBITDA

(4,954)

(2,578)

(5,743)

EBITDA (before exceptional items)

(1,874)

(2,507)

(5,017)

 

 

 

 

Licensing

Revenue is attributable to fees received or receivable in relation to the licensing of the Group's technology to third parties.

Other operating costs include all remaining costs unless they are directly attributable to Manufacturing or Research and Development. This includes marketing, business development and the majority of the Group's administration costs including the head office in Windsor as well as the US office. Headcount = 21 (2013: 21)

Manufacturing

Revenue includes the sale of Accoya® and other revenue, principally relating to the sale of acetic acid. All costs of sales are allocated against manufacturing activities in Arnhem unless they can be directly attributable to a licensee.

Other operating costs include depreciation of the Arnhem property, plant and equipment together will all other costs associated with the operation of the Arnhem manufacturing site, including directly attributable administration costs. Headcount = 77 (2013: 67)

Research and Development

Costs are associated with various R&D activities associated with Accoya® products and processes. The costs are reported excluding €128,000 of costs which have been capitalised in accordance with international financial reporting standards. (2013: €348,000).

Headcount = 14 (2013: 13)

 

Assets and liabilities cannot be readily allocated to the three segments and therefore no additional segmental information has been disclosed.

 

Analysis of revenue by geographical destination:

 

 

Unaudited

Unaudited

Audited

6 months

6 months

Year

ended

ended

ended

30 Sept

30 Sept

31 March

2014

2013

2014

€'000

€'000

€'000

 UK and Ireland

9,021

4,956

11,300

 Benelux

4,131

4,425

8,822

 Rest of Europe

5,636

3,691

7,501

 Americas

1,656

1,547

3,376

 Asia-Pacific

1,342

1,150

2,319

 Rest of World

-

-

194

21,786

15,769

33,512

 

The segmental assets in the current and previous periods were predominantly held in Europe. Additions to property, plant, equipment and intangible assets in the current and previous periods were predominantly incurred in Europe. Sales to UK and Ireland included the sales to Medite.

 

3. Other operating costs

 

Other operating costs consist of the operating costs, other than the cost of sales, associated with the operation of the plant in Arnhem and the offices in Dallas and Windsor.

 

Unaudited

Unaudited

Audited

6 months

6 months

Year

ended

ended

ended

30 Sept

30 Sept

31 March

2014

2013

2014

€'000

€'000

€'000

Sales and marketing

1,575

1,391

2,882

Research and development

461

553

1,151

Depreciation and amortisation

1,218

1,171

2,377

Other operating costs

1,480

1,225

2,243

Administration costs

2,911

2,417

5,594

Exceptional costs

3,080

71

726

10,725

6,828

14,973

 

Administrative costs include costs associated with the Human Resources, IT, Finance, Management, General Office, Business Development and Legal departments and include the costs of the Group's head office costs in Windsor and the US office in Dallas.

 

Exceptional costs relate to the arbitration with Diamond Wood - see note 4.

 

The Group headcount increased from 102 at 30 September 2013 to 109 at 31 March 2014 and then to 113 at 30 September 2014.

 

During the period €128,000 of development costs were capitalised and are included within intangible fixed assets (2013: €348,000). The prior year figure includes €169,000 in respect of the Accoya® licence Process Design Package.

 

 

4. Exceptional items

 

On 25 July 2014 Accsys announced that the arbitration tribunal (the "Tribunal") appointed in relation to the dispute between Accsys and Diamond Wood China Limited ("Diamond Wood") had delivered a 'First Partial Final Award' (the "Award").

 

In response to Diamond Wood's claim against Accsys, namely for damages in excess of €100 million as previously published by Diamond Wood, and for the continuation of the Licence Agreement, the Tribunal ruled that Diamond Wood can only claim for limited damages (if any) up to a maximum of €250,000. However, the Tribunal also ruled that the licence agreement between the two parties is to continue.

 

On 19 September 2014 Accsys announced that the Tribunal issued a final award in respect of costs relating to the Ruling which are payable to Diamond Wood, being approximately £1.6m.

 

The Exceptional item includes a provision for €2.4m in respect of the awards for damages and Diamond Wood's costs. In addition, Accsys has incurred a further €0.7m in respect of its own legal costs in the period. This is in addition to €0.7m incurred in previous financial year (€0.1m of which was incurred in the six months ended 30 September 2013) which has also been represented as an exceptional item in the respective periods which have been represented accordingly.

 

None of the €2.4m had been paid to Diamond Wood by 30 September 2014, however is expected to be in the third quarter of the financial year.

 

5. Loss per share

 

Unaudited

Unaudited

Unaudited

Unaudited

Audited

Audited

6 months

6 months

6 months

6 months

Year

Year

ended

ended

ended

ended

ended

ended

Basic and diluted loss per share

30 Sept2014

30 Sept2014

30 Sept2013

30 Sept2013

31 March2014

31 March2014

Before exceptional items

Total

Before exceptional items

Total

Before exceptional items

Total

Weighted average number ofOrdinary shares in issue ('000)

88,145

88,145

87,158

87,158

87,482

87,482

Loss for the period (€'000)

(3,622)

(6,702)

(4,060)

(4,131)

(8,163)

(8,889)

Basic and diluted loss per share

€(0.04)

€(0.08)

€(0.05)

€(0.05)

€(0.09)

€(0.10)

 

Basic and diluted losses per share are based upon the same figures. There are no dilutive share options as these would increase the loss per share.

 

The weighted average number of shares in issue has been re-presented for all periods to take account of the 5 to 1 share consolidation which became effective on 12 September 2014 (see note 8).

 

6. Share of joint venture losses

 

On 5 October 2012, Accsys entered into a 50:50 joint venture, Tricoya Technologies Limited ('TTL'), with INEOS to exploit Accsys' intellectual property surrounding its proprietary Tricoya® wood elements acetylation technology and processes, which is expected to lead to the accelerated global deployment of Tricoya.

 

TTL was granted rights to exploit Accsys' Tricoya® technology and also benefits from a licence of any intellectual property held by INEOS that may assist the joint venture in maximising the value of the Tricoya® proposition. Profits generated by TTL are to be shared between Accsys and INEOS in a way that reflects each party's interest. The contribution of Accsys' Tricoya® intellectual property to the Joint Venture will be reflected through a disproportionate future profit share which will create significant value for Accsys.

 

TTL has been accounted in the Accsys Group accounts using the equity method. The TTL results for the period from 1 April 2014 to 30 September 2014, together with the balance sheet as at 30 September 2014 are set out below:

 

 

Income statement for TTL joint venture:

 

Unaudited

Unaudited

Audited

6 months

6 months

Year

ended

ended

ended

30 Sept

30 Sept

31 March

2014

2013

2014

€'000

€'000

€'000

Licence revenue

225

100

153

Other income

239

-

-

Total revenue

464

100

153

Costs:

Staff costs

877

610

1,230

Research & development (excluding staff costs)

249

111

278

Intellectual Property

110

79

133

Sales & marketing

70

80

322

Amortisation

93

-

-

Total operating costs

1,399

880

1,963

Finance income

5

-

-

Joint venture loss

930

780

1,810

Group share of joint venture loss

465

390

905

 

Tricoya Technologies Limited statement of financial position at 30 September 2014:

 

 

Unaudited

Unaudited

Audited

6 months

6 months

Year

ended

ended

ended

30 Sept

30 Sept

31 March

2014

2013

2014

€'000

€'000

€'000

Non-current assets

Intangible assets

1,797

415

1,382

Current assets

Receivables due within one year

245

93

150

Cash and cash equivalents

125

465

499

Total current assets

370

558

649

Current liabilities

Trade and other payables

(727)

(814)

(1,302)

Net current assets

(357)

(256)

(653)

Net assets

1,440

159

729

50% attributable to Accsys Technologies

720

79

364

Less elimination of mark-up on recharged costs

(10)

(15)

(17)

 

 

 

 

 

 

 

Intangible assets represents internal development costs capitalised relating to the development of the Tricoya product and production process, including the production of the first process design package which will applied to the licence agreement with Medite.

 

During the period, TTL has benefited from the Life + Subsidy awarded by the EC. The subsidy, worth up to €2.1m over three years, was originally awarded to Accsys and Medite in 2013 and is intended for the benefit of the first Tricoya plant. €0.9m was received by Accsys in the prior year and will be transferred to TTL and Medite in the second half of the current financial year following the receipt of permission from the EC to formally transfer of the subsidy from Accsys to TTL. Therefore, TTL has recorded €239,000 of revenue in the as a result of having incurred eligible costs in the current and preceding periods.

 

7. Property, plant and equipment

 

Land and buildings

Plant and machinery

Office equipment

Total

€'000

€'000

€'000

€'000

Cost or valuation

At 31 March 2013

5,208

27,190

656

33,054

Additions

27

326

61

414

Disposals

-

-

-

-

At 30 September 2013

5,235

27,516

717

33,468

Additions

16

118

24

158

Disposals

-

(116)

-

(116)

Foreign currency translation gain/(loss)

-

-

(9)

(9)

At 31 March 2014

5,251

27,518

732

33,501

Additions

-

434

18

452

Disposals

-

-

-

-

Foreign currency translation gain/(loss)

-

-

9

9

At 30 September 2014

5,251

27,952

759

33,962

Depreciation

At 31 March 2013

192

10,057

534

10,783

Charge for the period

58

888

43

989

Disposals

-

-

-

-

At 30 September 2013

250

10,945

577

11,772

Charge for the period

57

931

48

1,036

Disposals

-

(40)

-

(40)

Foreign currency translation gain/(loss)

-

-

(7)

(7)

At 31 March 2014

307

11,836

618

12,761

Charge for the period

59

937

46

1,042

Disposals

-

-

-

-

Foreign currency translation gain/(loss)

-

-

8

8

At 30 September 2014

366

12,773

672

13,811

Net book value

At 31 March 2013

5,016

17,133

122

22,271

At 30 September 2013

4,985

16,571

140

21,696

At 31 March 2014

4,944

15,682

114

20,740

At 30 September 2014

4,885

15,179

87

20,151

 

 

8. Share capital

 

Further to the passing of all resolutions at the Company's AGM held on 11 September 2014, the entire issued share capital of the Company was consolidated on a 5:1 basis with effect from 12 September 2014. Accordingly, all figures concerning the number of shares stated below represent the new €0.05 Ordinary Shares.

 

Own shares represents 783,597 €0.05 Ordinary Shares issued to an Employee Benefit Trust ('EBT') at nominal value on 18 August 2014.

 

In addition, of the 953,133 €0.05 Ordinary Shares which had been issued to the EBT at nominal value on 9 July 2013, 945,133 Ordinary Shares vested on 8 August 2014. Of these beneficiaries elected to sell 361,033 Ordinary shares in the market. As at 30 September 2014, 223,425 Ordinary Shares remained pending sale by the EBT in the market.

 

On 18 August 2014, a total of 27,819 of €0.05 Ordinary shares were issued to a trust under the terms of the Employee Share Participation Plan.

 

On 12 August 2014, a total of 99,570 of €0.05 Ordinary shares were issued and released to employees together with the 99,570 of €0.05 Ordinary shares issued to trust on 12 August 2013.

 

 

 

9. Related party transactions

 

In the period ended 30 September 2014, there were a number of related party transaction with the Tricoya Technologies Limited joint venture, all of which arose in the normal course of business, totalling €758,000 (2013: €518,000). At the end of the period €425,000 of the total amount was payable from TTL to Accsys group companies (2013: €253,000).

 

 

 

 

Accsys Technologies PLC

 

Independent review report to Accsys Technologies PLC

 

Introduction

 

We have been engaged by the company to review the condensed consolidated set of financial statements in the half-yearly financial report for the six months ended 30 September 2014, which comprises the Consolidated statement of comprehensive income, Consolidated statement of financial position, Consolidated statement of changes in equity and the interim statement of cash flow and related notes. We have read the other information contained in the half-yearly financial report and considered whether it contains any apparent misstatements or material inconsistencies with the information in the condensed set of financial statements.

 

Directors' responsibilities

 

The half-yearly financial report is the responsibility of, and has been approved by, the directors. The directors are responsible for preparing the half-yearly financial report in accordance with the AIM and Euronext Amsterdam by NYSE Euronext Rules for Companies which require that the financial information must be presented and prepared in a form consistent with that which will be adopted in the company's annual financial statements.

 

As disclosed in note 1, the annual financial statements of the group are prepared in accordance with IFRSs as adopted by the European Union. The condensed set of financial statements included in this half-yearly financial report have been prepared in accordance with International Accounting Standard 34, "Interim Financial Reporting", as adopted by the European Union.

 

Our responsibility

 

Our responsibility is to express to the company a conclusion on the condensed set of financial statements in the half-yearly financial report based on our review. This report, including the conclusion, has been prepared for and only for the company for the purpose of the AIM and Euronext Amsterdam by NYSE Euronext Rules for Companies and for no other purpose. We do not, in producing this report, accept or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come save where expressly agreed by our prior consent in writing.

 

Scope of review

 

We conducted our review in accordance with International Standard on Review Engagements (UK and Ireland) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Auditing Practices Board for use in the United Kingdom. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing (UK and Ireland) and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

 

Conclusion

 

Based on our review, nothing has come to our attention that causes us to believe that the condensed set of financial statements in the half-yearly financial report for the half year ended 30 September 2014 is not prepared, in all material respects, in accordance with International Accounting Standard 34, "Interim Financial Reporting", as adopted by the European Union, the AIM and Euronext Amsterdam by NYSE Euronext Rules for Companies.

 

 

PricewaterhouseCoopers LLPChartered Accountants

London

 

21 November 2014

 

Notes:

 

a) The maintenance and integrity of the Accsys Technologies PLC website is the responsibility of the directors; the work carried out by the auditors does not involve consideration of these matters and, accordingly, the auditors accept no responsibility for any changes that may have occurred to the interim financial report since it was initially presented on the website.

b) Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR LFFLLLTLVFIS
Date   Source Headline
28th Mar 202412:00 pmRNSDirector Interests
1st Mar 20247:00 amRNSBlock listing Six Monthly return
27th Feb 20247:00 amRNSBlock listing application to AIM
12th Dec 20237:00 amRNSDirectorate Change
27th Nov 20239:57 amRNSNotifiable Interest - De Engh B.V.
27th Nov 20239:33 amRNSNotifiable Interest – Teslin
24th Nov 202312:21 pmRNSNotifiable Interest – De Engh B.V.
21st Nov 20233:37 pmRNSResults of Capital Raise
21st Nov 20237:04 amRNSHalf-year Report
21st Nov 20237:00 amRNSIssue of Equity
20th Sep 20235:12 pmRNSResults of Annual General Meeting 2023
15th Sep 20233:54 pmRNSNotifiable Interest - De Engh
12th Sep 20237:00 amRNSDirectorate Change
1st Sep 20237:00 amRNSBlock Listing Six Monthly Return
1st Sep 20237:00 amRNSTotal Voting Rights
1st Sep 20237:00 amRNSTrading Update
17th Aug 20235:01 pmRNSNotice of Annual General Meeting 2023
28th Jul 20237:00 amRNSDirector Interests and LTIP Awards
26th Jul 20237:00 amRNSDirectorate Appointment
21st Jul 20233:46 pmRNSAnnual Report and Financial Statements 2023
27th Jun 20237:00 amRNSPreliminary results for the year end 31 March 2023
19th Jun 202312:48 pmRNSChange of Registered Office
6th Jun 20237:00 amRNSDirectorate Update
12th May 202311:21 amRNSBlock Listing Application to AIM
3rd May 20237:00 amRNSTrading Update
4th Apr 20237:00 amRNSCEO Appointment
24th Mar 20237:00 amRNSDirectorate Appointments
2nd Mar 20236:00 pmRNSBlock Listing Six Monthly Return
2nd Mar 20236:00 pmRNSTotal Voting Rights
26th Jan 20237:00 amRNSAccsys Trading Update
15th Dec 20223:55 pmRNSDirector/PDMR Shareholding
12th Dec 20227:00 amRNSDirectorate Change
6th Dec 20223:43 pmRNSNotifiable Interest - De Engh
6th Dec 20223:36 pmRNSNotifiable Interest - Teslin Participaties
22nd Nov 20227:00 amRNSInterim Results for six months ended 30 Sept 2022
17th Nov 20222:58 pmRNSIssue of Equity
10th Nov 20224:37 pmRNSHolding(s) in Company
8th Nov 20225:09 pmRNSHolding(s) in Company
2nd Nov 20227:00 amRNSUpdate on Tricoya – Consortium restructure
1st Nov 20224:12 pmRNSNotice of HY Results and Total Voting Rights
23rd Sep 20224:20 pmRNSResult of AGM
12th Sep 20227:00 amRNSAccsys Trading Update
23rd Aug 20224:49 pmRNSNotice of AGM
23rd Aug 20222:35 pmRNSBlock Listing Application to AIM
3rd Aug 20227:00 amRNSDirectorate Change
27th Jul 20225:56 pmRNSAnnual Report
12th Jul 202210:40 amRNSDirector Interests and LTIP Awards
12th Jul 202210:16 amRNSGrant of Awards under Accsys Deferred Bonus Plan
30th Jun 20227:00 amRNSPreliminary results for the year end 31 March 2022
10th Jun 20227:00 amRNSBoard Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.